Evidence shows that breast cancer cells treated with doxorubicin increased PCho/GPC ratio caused by a downregulation of the enzymes PLD1, GDPD6, and ChoKα (Figure 2). The gene discussed is GPCPD1; the disease is breast carcinoma.